Consolidated Balance Sheets (USD $)	Sep. 30, 2012		Dec. 31, 2011
Current assets
Cash	$ 332,862		$ 952,252
Prepaid drug product for testing	79,500		153,000
Other current assets	45,395		48,439
Total current assets	457,757		1,153,691
Other assets
Technology licenses - related party	2,500,374		2,868,877
Less Accumulated Amortization	(888,075)		(791,463)
Intangible Assets, Net (Excluding Goodwill), Total	1,612,299		2,077,414
TOTAL ASSETS	2,070,056		3,231,105
Current liabilities
Accounts payable	65,423		121,540
Accounts payable - related party	8,582		67,971
Accrued expense	105,567		46,082
Accrued expense - related party	39,000		41,000
Accrued license payments - related party	50,000		39,538
Total current liabilities	268,572		316,131
Long term debt
TOTAL LIABILITIES	268,572		316,131
Shareholders' Equity
Preferred Stock, $.001 par value 10,000,000 shares authorized, no shares issued and outstanding
Common Stock, $.001 par value, 200,000,000 shares authorized 58,918,713 and 58,325,169 shares issued and outstanding as of 9/30/12 and 12/31/11, respectively	58,918		58,325
Additional paid in capital	12,496,929		12,405,395
Additional paid in capital for shares to be issued	945,001	[1]		[1]
Accumulated deficit during development stage	(11,699,364)		(9,548,746)
Total shareholders' equity	1,801,484		2,914,974
TOTAL LIABILITIES & SHAREHOLDERS' EQUITY	$ 2,070,056		$ 3,231,105

[1] Represents 3,150,003 shares of common stock